Further advice on scheduling of cannabis-derived medicinal products

Further advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.


ACMD response letter on cannabis-derived medicinal products

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


Letter from the ACMD chair, Dr Owen Bowden-Jones, to the Home Secretary Sajid Javid and Secretary of State for Health and Social Care Matt Hancock, responding to the consultation on a proposed definition of cannabis-derived medicinal products.

This follows the ACMD’s initial short-term advice recommending products meeting this definition are moved out of the requirements of schedule 1.

Published 11 September 2018